Download PDF
CC BY-NC-ND 4.0 · Endosc Int Open 2018; 06(03): E300-E307
DOI: 10.1055/s-0044-101351
Original article
Owner and Copyright © Georg Thieme Verlag KG 2018

Adherence to quality indicators and surveillance guidelines in the management of Barrett’s esophagus: a retrospective analysis

Donevan Westerveld
1   Department of Internal Medicine, University of Florida, Gainesville, FL, USA
,
Vikas Khullar
2   Division of Gastroenterology and Hepatology, University of Florida, Gainesville, FL, USA
,
Lazarus Mramba
3   Statistics, Department of Internal Medicine, University of Florida, Gainesville, FL, USA
,
Fares Ayoub
1   Department of Internal Medicine, University of Florida, Gainesville, FL, USA
,
Tony Brar
1   Department of Internal Medicine, University of Florida, Gainesville, FL, USA
,
Mitali Agarwal
1   Department of Internal Medicine, University of Florida, Gainesville, FL, USA
,
Justin Forde
1   Department of Internal Medicine, University of Florida, Gainesville, FL, USA
,
Joydeep Chakraborty
1   Department of Internal Medicine, University of Florida, Gainesville, FL, USA
,
Michael Riverso
2   Division of Gastroenterology and Hepatology, University of Florida, Gainesville, FL, USA
,
Yaseen B. Perbtani
2   Division of Gastroenterology and Hepatology, University of Florida, Gainesville, FL, USA
,
Anand Gupte
2   Division of Gastroenterology and Hepatology, University of Florida, Gainesville, FL, USA
,
Chris E. Forsmark
2   Division of Gastroenterology and Hepatology, University of Florida, Gainesville, FL, USA
,
Peter Draganov
2   Division of Gastroenterology and Hepatology, University of Florida, Gainesville, FL, USA
,
Dennis Yang
2   Division of Gastroenterology and Hepatology, University of Florida, Gainesville, FL, USA
› Author Affiliations
Further Information

Publication History

submitted 05 November 2017

accepted after revision 18 December 2017

Publication Date:
01 March 2018 (online)

Also available at
   Permissions and Reprints

Abstract

Background Adherence to quality indicators and surveillance guidelines in the management of Barrett’s esophagus (BE) promotes high-quality, cost-effective care. The aims of this study were (1) to evaluate adherence to standardized classification (Prague Criteria) and systematic (four-quadrant) biopsy protocol, (2) to identify predictors of practice patterns, and (3) to assess adherence to surveillance guidelines for non-dysplastic BE (NDBE).

Methods This was a single-center retrospective study of esophagogastroduodenoscopy (EGD) performed for BE (June 2008 to December 2015). Patient demographics, procedure characteristics, and histology results were obtained from the procedure report-generating database and chart review. Adherence to Prague Criteria and systematic biopsies was based on operative report documentation. Multiple logistic regression analysis was performed to identify predictors of practice patterns. Guideline adherent surveillance EGD was defined as those performed within 6 months of the recommended 3- to 5-year interval.

Results In total, 397 patients (66.5 % male; mean age 60.1 ± 12.5 years) had an index EGD during the study period. Adherence to Prague Criteria and systematic biopsies was 27.4 % and 24.1 %, respectively. Endoscopists who performed therapeutic interventions for BE were more likely to use the Prague Criteria (OR: 3.16; 95 %CI: 1.47 – 6.82; P < 0.01) than those who did not. Longer time in practice was positively associated with adherence to Prague Criteria (OR 1.07; 95 %CI: 1.02 – 1.12; P < 0.01) but with a lower likelihood of performing systematic biopsies (OR 0.91; 95 %CI: 0.85 – 0.97; P < 0.01). More than half (55.6 %) of patients with NDBE underwent surveillance EGD sooner (range 1 – 29 months) than the recommended interval.

Conclusion Adherence to quality indicators and surveillance guidelines in BE is low. Operator characteristics, including experience with endoscopic therapy for BE and time in practice predicted practice pattern. Future efforts are needed to reduce variability in practice and promote high-value care.

 

  • References

  • 1 De Jonge PJ, van Blankenstein M, Looman CW. et al. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut 2010; 59: 1030-1036
    CrossrefPubMedGoogle Scholar
  • 2 Hvid-Jensen F, Pedersen L, Drewes AM. et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. NEJM 2011; 365: 1375-1383
    CrossrefPubMedGoogle Scholar
  • 3 Solaymani-Dodaran M, Card TR, West J. Cause-specific mortality of people with Barrett’s esophagus compared with the general population: a population-based cohort study. Gastroenterology 2013; 144: 1375-1383
    CrossrefPubMedGoogle Scholar
  • 4 Edgren G, Adami HO, Weiderpass E. et al. A global assessment of the oesophageal adenocarcinoma epidemic. Gut 2013; 62: 1406-1414
    CrossrefPubMedGoogle Scholar
  • 5 Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett’s esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 2005; 3: 1-10
    CrossrefPubMedGoogle Scholar
  • 6 El-Serag HB, Naik AD, Duan Z. et al. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett’s oesophagus. Gut 2016; 65: 1252-1260
    CrossrefPubMedGoogle Scholar
  • 7 Spechler SJ, Sharma P, Souza RF. et al. American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology 2011; 140: 1084-1091
    CrossrefPubMedGoogle Scholar
  • 8 Shaheen NJ, Falk GW, Iyer PG. et al. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. Am J Gastroenterol 2016; 111: 30-50
    CrossrefPubMedGoogle Scholar
  • 9 Weusten B, Bisschops R, Coron E. et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017; 49: 191-198
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Evans JA, Early DS, Fukami N. et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc 2012; 76: 1087-1094
    CrossrefPubMedGoogle Scholar
  • 11 Sharma P, Dent J, Armstrong D. et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology 2006; 131: 1392-1399
    CrossrefPubMedGoogle Scholar
  • 12 Abela J-E, Going J, Mackenzie J. et al. Systematic four-quadrant biopsy detects Barrett’s dysplasia in more patients than nonsystematic biopsy. Am J Gastroenterol 2008; 103: 850-855
    CrossrefPubMedGoogle Scholar
  • 13 Falk GW, Ours TM, Richter JE. Practice patterns for surveillance of Barrett’s esophagus in the United States. Gastrointest Endosc 2000; 52: 197-203
    CrossrefPubMedGoogle Scholar
  • 14 Singh M, Gupta N, Gaddam S. et al. Practice patterns among U.S. gastroenterologists regarding endoscopic management of Barrett’s esophagus. Gastrointest Endosc 2013; 78: 689-695
    CrossrefPubMedGoogle Scholar
  • 15 Menezes A, Tierney A, Yang YX. et al. Adherence to the 2011 American Gastroenterological Association medical position statement for the diagnosis and management of Barrett’s esophagus. Dis Esophagus 2015; 28: 538-546
    CrossrefPubMedGoogle Scholar
  • 16 Schlemper RJ. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-255
    CrossrefPubMedGoogle Scholar
  • 17 Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol 2008; 140: 1084-1091
    PubMedGoogle Scholar
  • 18 Gopal DV, Lieberman DA, Margaret N. et al. Risk factors for dysplasia in patients with Barrett’s esophagus (BE): results from a multicenter consortium. Dig Dis Sci 2003; 48: 1537-1541
    CrossrefPubMedGoogle Scholar
  • 19 Menke-Pluymers MB, Hop WC, Dees J. et al. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. Cancer 1993; 72: 1155-1158
    CrossrefPubMedGoogle Scholar
  • 20 Sharma P, Katzka DA, Gupta N. et al. Quality indicators for the management of Barrett’s esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology 2015; 149: 1599-1606
    CrossrefPubMedGoogle Scholar
  • 21 Dunn SJ, Neilson LJ, Hassan C. et al. ESGE Survey: worldwide practice patterns amongst gastroenterologists regarding the endoscopic management of Barrett’s esophagus. Endosc Int Open 2016; 04: E36-E41
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Abrams JA, Kapel RC, Lindberg GM. et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol 2009; 7: 736-742
    CrossrefPubMedGoogle Scholar
  • 23 Curvers WL, Peters FP, Elzer B. et al. Quality of Barrett's surveillance in The Netherlands: a standardized review of endoscopy and pathology reports. Eur J Gastroenterol Hepatol 2008; 20: 601-607
    CrossrefPubMedGoogle Scholar
  • 24 Swager A, van der Sommen F, Klomp SR. et al. Computer-aided detection of early Barrett’s neoplasia using volumetric laser endomicroscopy. Gastrointest Endosc 2017; 86: 839-846
    CrossrefPubMedGoogle Scholar
  • 25 Maes S, Sharma P, Bisschops R. Review: Surveillance of patients with Barrett’s oesophagus. Best Pract Res Clin Gastroenterol 2016; 30: 901-912
    PubMedGoogle Scholar
  • 26 Katzka DA. Recent advances in non-invasive esophageal tissue sampling. Curr Gastroenterol Rep 2017; 19: 9
    CrossrefPubMedGoogle Scholar
  • 27 Gaddam S, Singh M, Balasubramanian G. et al. Persistence of nondysplastic Barrett’s esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. Gastroenterology 2013; 145: 548-553
    CrossrefPubMedGoogle Scholar
  • 28 Wani S, Falk G, Hall M. et al. Patients with nondysplastic Barrett’s esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011; 9: 220-227
    CrossrefPubMedGoogle Scholar
  • 29 Nieto T, Tomlinson CL, Dretzke J. et al. Epigenetic biomarkers in progression from non-dysplastic Barrett’s oesophagus to oesophageal adenocarcinoma: a systematic review protocol. BMJ Open 2016; 7: e013361
    PubMedGoogle Scholar
  • 30 Gatenby P, Bhattacharjee S, Wall C. et al. Risk stratification for malignant progression in Barrett’s esophagus: gender, age, duration and year of surveillance. World J Gastroenterol 2016; 22: 10592-10600
    CrossrefPubMedGoogle Scholar
  • 31 Gould JC, Wendling MR, Oeschlager BK. et al. Advances in the diagnosis and treatment of Barrett’s esophagus and early esophageal cancer; Summary of the Kelly and Carlos Pellegrini SSAT/SAGES Luncheon Symposium. J Gastrointest Surg 2017; 21: 1342-1349
    CrossrefPubMedGoogle Scholar